Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (6029)	10/14/1998 3:59:00 PM
From: twt	Read Replies (2) \| Respond to of 9523

This is news to me. Havent heard of it. What do you think of today's stock action? Short covering, upgrade, or someone sees something promising in their earnings report, or just one of those things that no can can seem to explain? :-) I was bracing for a 'bad' day so to speak but turned out to be 'WOW' day! However MTC was a different story. What puzzle me (in regards to MTC) is that PFE had already spent so much in preparation for Celebra. It would seem to me that PFE is more than confident that Celebra wil be approved soon by the FDA. Given all the good medical reviews we had read on Celebra, MTC should be higher than todays price... what you guys/gals think? Good luck to all. Have good day.

To: Anthony Wong who wrote (6029)	10/14/1998 4:49:00 PM
From: John F. Dowd	Read Replies (1) \| Respond to of 9523

Dear Anthony: From PFE 1997 annual report"Building on the strength of our in-line products, Pfizer is forging ahead with an ambitious R&D program, with more than 170 research projects in discovery and development—more than at any time in our history. In1998, we expect to file for approval of two major new drugs: Tikosyn (dofetilide) to treat atrial fibrillation and Eletriptan for the treatment of migraines. We also plan to file for supplemental indications for Norvasc and Zoloft. John